Sangamo Therapeutics Regains Control of Hemophilia A Gene Therapy
A New Chapter for Giroctocogene Fitelparvovec
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, a promising gene therapy product candidate for moderately severe to severe hemophilia A. This move comes after Pfizer Inc (NYSE:PFE) decided to terminate their global collaboration and license agreement.
Pfizer’s Decision Sparks Surprise and Disappointment
The news came as a surprise to Sangamo Therapeutics, with CEO Sandy Macrae expressing extreme disappointment at Pfizer’s decision to end their collaboration just as the program was nearing regulatory submissions and potential commercialization. Despite this setback, Macrae remains confident in the product’s potential, citing its success in meeting primary and key secondary objectives in the Phase 3 AFFINE trial.
Exploring New Opportunities
Sangamo Therapeutics is now exploring all options to advance the program, including seeking a new collaboration partner. The company believes its recent partnerships with Roche Holdings AG’s (OTC:RHHBY) Genentech and Astellas Pharma Inc (OTC:ALPMF) (OTC:ALPMY) will provide a strong foundation for its neurology genomic medicine pipeline.
Pipeline Progress
Sangamo Therapeutics is preparing to initiate patient enrollment in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and file a Clinical Trial Authorisation submission for the prion disease program in Q4 2025, pending additional funding.
Market Impact
The news has had a significant impact on Sangamo Therapeutics’ stock, which plummeted 54.70% to $1.106 in premarket trading on Tuesday. Despite this, the company remains committed to advancing its pipeline and exploring new opportunities for growth.
What’s Next?
As Sangamo Therapeutics charts a new path forward, investors will be watching closely to see how the company navigates this transition. With its strong pipeline and recent partnerships, the future looks promising for this gene therapy pioneer.
Leave a Reply